SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x                              QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH  31, 2007.

OR

o                                 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM              TO             .

Commission File Number   0-18592

MERIT MEDICAL SYSTEMS, INC.

(Exact name of Registrant as specified in its charter)

1600 West Merit Parkway, South Jordan, UT, 84095

(Address of Principal Executive Offices)

(801) 253-1600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  x  No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  o  No  x

Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of the latest practicable date.

MERIT MEDICAL SYSTEMS, INC.

INDEX TO FORM 10-Q

2

Part I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

MARCH 31, 2007 AND DECEMBER 31, 2006
(In Thousands - Unaudited)

See notes to consolidated financial statements.

3

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

MARCH 31, 2007 AND DECEMBER 31, 2006
(In Thousands - Unaudited)

See notes to consolidated financial statements.

4

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH  31, 2007 AND 2006

(In Thousands, Except Earnings per Share and Unaudited)

See notes to consolidated financial statements.

5

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006

(In Thousands and Unaudited)

See notes to consolidated financial statements.

6

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2007

(In Thousands and Unaudited)

See notes to consolidated financial statements.

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

During the first quarter of 2007, we acquired other intangibles (Customer Relationships) of Medrad, a Swedish Company, in a purchase transaction for $124,036.  The purchase price was allocated to other intangibles  (Customer Relationships) for $124,036.

7

During the first quarter of 2007, we entered into a distribution Agreement with Milamy Partners LLC, (“Milamy”) a Maine corporation, wherein we purchased the exclusive, worldwide right to distribute their KanguruWeb™ Abdominal Retraction System in the vascular lab markets for $350,000.   As part of the distribution agreement, we received a customer list for the distribution agreements terminated by Milamy for their domestic and international sales to vascular labs.  The purchase price was allocated to other intangibles (Customer Relationships) for $350,000.

In the first quarter of 2007, we entered into an asset purchase agreement with Datascope Corporation, a New Jersey corporation, to purchase its ProGuide™ catheter in a purchase transaction for $3.0 million dollars.   In connection with this agreement we acquired assets, inventory, customer list, patents and trademarks.  We plan to complete our asset valuation during the second quarter of 2007.  The purchase price was preliminarily allocated to fixed assets for $50,844, inventory for $806,507 and goodwill for $2,142,649, which is subject to change upon completion of our asset valuation.  

See notes to consolidated financial statements.

8

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.  Basis of Presentation. The interim consolidated financial statements of Merit Medical Systems, Inc. (“Merit,” “we” or “us”) for the three months ended March 31, 2007 and 2006 are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods, and consequently, do not include all disclosures required to be in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of March 31, 2007, and our results of operations and cash flows for the three months ended March 31, 2007 and 2006. The results of operations for the three months ended March 31, 2007 are not necessarily indicative of the results for a full-year period.  These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission (the “SEC”).

Reclassifications.  Certain amounts have been reclassified in the prior year’s financials to conform with the current year’s presentation.

 2.   Inventories.  Inventories are stated at the lower of cost or market.  Inventories at March 31, 2007 and December 31, 2006 consisted of the following (in thousands):

3.  Reporting Comprehensive Income.  Comprehensive income for the three months ended March 31, 2007 and 2006 consisted of net income and foreign currency translation adjustments.  As of March 31, 2007 and December 31, 2006, the cumulative effect of such adjustments reduced stockholders’ equity by $139,460 and $151,048 respectively.  Comprehensive income for the three-month periods ended March 31, 2007 and 2006 has been computed as follows (in thousands):

4. Stock-based Compensation.  No stock awards were granted during the three-month periods ended March 31, 2007 and 2006.  Total pre-tax stock-based compensation expense for the three-month periods ended March 31, 2007 and 2006 was $147,000 ($14,000 in cost of goods sold, $5,000 in research and development and $128,000 in selling, general and administrative expense) and $390,000 ($116,000 in cost of goods sold, $48,000 in research and development and $226,000 in selling, general and administrative expense), respectively.  This stock-based compensation created a tax benefit of $132,000 and $169,000 for the three-months ended March 31, 2007 and 2006, respectively. As of March 31, 2007, the total remaining unrecognized compensation cost related to non-vested stock options, net of forfeitures, was approximately $1.1 million and is expected to be recognized over a weighted average period of 0.83 years.

9

5. Acquisitions.  On February 14, 2007, we terminated our exclusive sales distributor agreement with Medrad Sweden, and purchased the customer list and information we believe will be necessary for us to conduct direct sales in Sweden.  The purchase price of $124,036 was allocated to other intangibles (Customer Relationships).  Customer relationships will be amortized on an accelerated basis over 5 years.

On February 2, 2007, we entered into a distribution agreement with Milamy Partners LLC, a Maine corporation, wherein Milamy granted to us an exclusive worldwide right to distribute the KanguruWeb™ Abdominal Retraction System in the vascular lab markets. Milamy terminated their current domestic and international distribution agreements and restricted their direct sales to non-vascular lab markets only.  We paid $350,000 for the exclusive worldwide distribution rights, which amount was allocated to other intangibles (Customer Relationships). The KanguruWeb™ Abdominal Retraction System provides retraction of the abdominal pannus for unrestricted access to the femoral site.

On February 26, 2007, we entered into an Asset Purchase Agreement with Datascope Corporation, a New Jersey corporation, to purchase certain assets for the manufacturing and sale of the ProGuide™ catheter for $3.0 million.    In connection with this agreement, we acquired assets, inventory, customer list, patents and trademarks.  We plan to complete our asset valuation during the second quarter of 2007.  The purchase price was preliminarily allocated to fixed assets for $50,844, inventory for $806,507 and goodwill for $2,142,649, which is subject to change upon completion of our assets valuation.  The ProGuide™ catheter is a chronic dialysis catheter used in attaining long-term vascular access for hemodialysis and apheresis.

6. Recent Accounting Pronouncements.  In September 2006,  the Financial Accounting Standards Board (“FASB”) issued the Statement of Financial Accounting Standards (“SFAS”) No. 157 “Fair Value  Measurements.”  This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value.  SFAS 157 expands the disclosures about the use of fair value to measure assets and liabilities in interim and annual periods subsequent to initial recognition. The disclosures focus on the inputs used to measure fair value, the recurring fair value measurements using significant  unobservable inputs and the effect of the measurement on earnings (or changes in net assets) for the period.  The guidance in SFAS 157 also applies for  derivatives  and other  financial instruments   measured  at  fair  value  under  Statement  133 “Accounting  for Derivative Instruments and Hedging Activities” at initial recognition and in all subsequent periods. SFAS 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.  We are currently reviewing the requirements of SFAS 157, and at this point in time, have not determined what impact, if any, SFAS 157 will have on our results of operations and financial position.

In February 2007, the FASB issued SFAS 159 “The Fair Value Option for Financial Assets and Financial Liabilities.”  This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently  required to be measured at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions.  This statement requires a business entity to report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date.  An entity may decide whether to elect the fair value option for each eligible item on its election date, subject to certain requirements described in the statement. SFAS 159 is effective for fiscal years beginning after November 15, 2007.  We are currently reviewing the requirements of this statement and, at this point in time, have not determined the impact, if any, that this statement may have on our results of operations and financial position.

7.  Income Taxes.   In July 2006, the FASB issued Interpretation No. 48 (“FIN 48”), Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FASB Statement No. 109, Accounting for Income Taxes. Under FIN 48, tax positions shall initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts.

We adopted the provisions of FIN 48 on January 1, 2007.  As a result of this adoption, we recognized a cumulative-effect adjustment of approximately $610,000, increasing our liability for unrecognized tax benefits and reducing the January 1, 2007 balance of retained earnings.  The total liability for unrecognized tax benefits at January 1, 2007, including temporary tax differences, was approximately $3.4 million, of which approximately $1.7 million would favorably impact our effective tax rate if recognized. As of January 1, 2007, we accrued

10

approximately $228,000 in interest and penalties related to unrecognized tax benefits. We account for interest expense and penalties for unrecognized tax benefits as part of our income tax provision.  We do not anticipate that unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date.

During the first quarter of 2007, we recorded approximately $163,000 related to unrecognized tax benefits that would favorably impact our effective tax rate if recognized.   Included in this amount is approximately $41,000 related to interest expense and penalties.   The total outstanding balance for liabilities related to unrecognized tax benefits at March 31, 2007 was $3.7 million.

Our federal and state income tax returns for 2002 through 2006 are open tax years.  We are in several foreign tax jurisdictions which have open tax years from 2002 through 2006.

8.  Subsequent Events.   On April 2, 2007, we repurchased 344,084 shares of our common stock in a private transaction with a non-institutional private investor for an aggregate transaction price of $4,059,159, or $11.80 per share.

11

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Disclosure Regarding Forward-Looking Statements

This Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  All statements in this Report, other than statements of historical fact, are forward-looking statements for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing.  All forward-looking statements included in this Report are made as of the date hereof and are based on information available to us as of such date.  We assume no obligation to update any forward-looking statement.   In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,”  “intends,” “believes,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terminology.  Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that any such expectations or any forward-looking statement will prove to be correct.  Our actual results may vary, and may vary materially, from those projected or assumed in the forward-looking statements.  Future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, without limitation, market acceptance of our products, product introductions, potential product recalls, delays in obtaining regulatory approvals, or the failure to maintain such approvals, cost increases, fluctuations in and obsolescence of inventory, price and product competition, availability of labor and materials, development of new products and technology that could render our products obsolete, product liability claims, modification or limitation of governmental or private insurance reimbursement procedures, infringement of our technology or the assertion that our technology infringes the rights of other parties, foreign currency fluctuations, challenges associated with our growth strategy, changes in healthcare markets related to healthcare reform initiatives, and other factors referred to in our press releases and reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2006. All subsequent forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements.  Additional factors that may have a direct bearing on our operating results are discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2006.

Overview

For the quarter ended March 31, 2007, we reported revenues of $51.0 million, up 13% over the three months ended March 31, 2006.

Gross profit as a percentage of sales were down to 37.0% for the first quarter of 2007, compared to 37.9% for the first quarter of 2006. This decline can be attributed primarily to an increase in wages beginning in the fourth quarter of 2006, additional headcount, higher health benefit costs, and increases in depreciation of new production equipment when compared to the comparable period in 2006.  We completed the transfer of one of our product lines to a contract manufacturer in Mexico during the first quarter of 2007, and intend to have three additional product lines moved by the end of 2007.   We believe these transfers will help to reduce our direct labor cost per unit upon completion of each move and free up manufacturing support costs that can be reduced or applied to support new products.  In addition, we continue to work to develop manufacturing efficiencies, raise some customer prices, discontinue some lower-margin business, and we plan to launch our newly-acquired version of the chronic dialysis catheter, which we believe will have a higher gross margin than our current overall gross margins.

Net income increased for the three months ended March 31, 2007 to $3.0 million, compared to $2.4 million for the prior year period, an increase of 24%.  When compared to the prior year period, net income for the quarter ended March  31, 2007 was positively affected by increased sales volumes and lower selling, general and administrative expenses as a percentage of sales, and a lower effective income tax rate and negatively affected by lower gross margins.

12

Results of Operations

The following table sets forth certain operational data as a percentage of sales for the three months ended March 31, 2007 and 2006:

Sales.  Sales for the three months ended March 31, 2007 increased by 13%, or approximately $6.0 million, compared to the same period of 2006.    We report sales in four product categories.  Listed below are the sales relating to these product categories for the three months ended March 31, 2007 and 2006:

The sales growth of 13% for the first quarter of 2007, when compared to the same period of the prior year, was favorably affected by a 5.5% increase in sales of several stand-alone devices due primarily to the introduction of new products and growth in some Original Equipment Manufacturing (“OEM”) business, a 5.2% increase in custom kits and procedure tray business, of which nearly half came from procedure tray sales, and a 2.2% increase in catheter sales, largely from our Prelude and Mini Access Kit product lines.

Gross Profit.  Gross profit as a percentage of sales declined to 37.0% for the first quarter of 2007, compared to 37.9% of sales for the comparable period. This decline can be attributed primarily to an increase in wages beginning in the fourth quarter of 2006, additional headcount, higher health benefit costs, and increases in depreciation of new production equipment when compared to the first quarter of 2006.

Operating Expenses.  Selling, general and administrative expenses decreased to 23.5% of sales for the three months ended March 31, 2007, compared with 25.0% of sales for the three months ended March 31, 2006.  The decrease in selling, general and administrative expenses as a percentage of sales during the three months ended March 31, 2007, when compared to the first three months of 2006, was due primarily to increased operating leverage resulting, in large part, from hiring 17 additional sales representatives during the second half of 2005.  Research and development expenses remained unchanged at 4.6% of sales for the three months ended March 31, 2007 and 2006.

13

Other Income.  Other income for the first quarter of 2007 was approximately $88,000, compared to approximately $18,000 for the same period in 2006.  This increase in other income during the first quarter of 2007, when compared to the same period in 2006, was primarily the result of an increase in interest income as the result of a higher average cash balance and higher interest rates for the quarter ended March 31, 2007, when compared to the same period of 2006.

Income Taxes.  Our effective tax rate for the three months ended March 31, 2007 was 35.0%, compared to 36.0% for the same period of 2006.  The decrease in the effective tax rate for March 31, 2007, when compared to the same period of 2006, was primarily the result of newly enacted research and development tax credit laws which increased our benefit.

Income.  During the first quarter of 2007, we reported income from operations of $4.5 million, an increase of 20% from $3.7 million for the comparable period in 2006.  When compared to the comparable period of 2006, income from operations for the quarter ended March 31, 2007 was positively affected by increased sales volumes and lower selling, general and administrative expenses, and negatively affected by lower gross margins. These factors, along with a lower effective tax rate for the three months ended March 31, 2007 compared to the comparable period of 2006, contributed to increased net income of $3.0 million, an increase of 24%, for the three months ended March 31, 2007, when compared to net income of $2.4 million for the same period of 2006.

Liquidity and Capital Resources

Our working capital as of March 31, 2007 and December 31, 2006 was $54.5 million and $55.0 million, respectively.  As of March 31, 2007, we had a current ratio of 3.5 to 1. On December 7, 2006, we entered into an unsecured loan agreement with Bank of America, whereby they agreed to provide us a line of credit in the amount of $30,000,000, expiring on December 7, 2010. In addition, on December 8, 2006, we entered into an unsecured loan agreement with Zion’s First National Bank, whereby they agreed to provide us with a line of credit in the amount of $1,000,000. We had $0 outstanding under our lines of credit at March 31, 2007.  We generated cash from operations for the three months ended March 31, 2007, in the amount of $5.8 million.

Historically, we have incurred significant expenses in connection with product development and introduction of new products.  Substantial capital has also been required to finance the increase in our receivables and inventories associated with our increased sales. Our principal source of funding for these and other expenses has been cash generated from operations, sale of equity, cash from loans on equipment, and bank lines of credit.  We currently believe that our present sources of liquidity and capital are adequate for current operations and for the foreseeable future.

Contractual Obligations Table

We have certain fixed contractual lease and royalty obligations that include future estimated payments.  These  commitments are discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 in our Management’s Discussion and Analysis of Financial Condition and Result of Operations under “Capital Commitments.”  We adopted the provisions of FIN 48 for unrecognized tax positions on January 1, 2007.  We are subject to income tax audits by federal, state and foreign tax authorities.   If under examination by tax authorities we are unsuccessful in our unrecognized tax positions, future tax payments may be required.    Although, we are currently under audit by the Internal Revenue Service for years 2002 and 2004, we are unaware of any material future payments that may be required at this time related to these ongoing audits.  

Critical Accounting Policies and Estimates

The SEC has requested that all registrants address their most critical accounting policies.  The SEC has indicated that a “critical accounting policy” is one which is both important to the representation of the registrant’s financial condition and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.  We base our estimates on past experience and on various other assumptions our management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources.  Actual results will differ, and may differ materially from these estimates under different assumptions or conditions.  Additionally, changes in accounting estimates could occur in the future from period to period.  Our management has discussed the development, and selection of our most critical financial estimates with the Audit Committee of our Board of Directors.  The following paragraphs identify our most critical accounting policies:

Inventory Obsolescence Reserve:  Our management reviews on a regular basis inventory quantities on hand for unmarketable and/or slow-moving products that may expire prior to being sold.  This review of inventory quantities for unmarketable and/or slow moving products is based on estimates of forecasted product demand prior to expiration dates.  If market conditions become less favorable than those projected by our management, then additional inventory write-downs may be required.  We believe that the amount included in our obsolescence reserve has been a historically accurate estimate of the unmarketable and/or slow moving products that may expire prior to being sold.  Our obsolescence reserve was approximately $2.2 million as of March 31, 2007.

14

Allowance for Doubtful Accounts:  A majority of our receivables are with hospitals which, over our history, have demonstrated favorable collection rates.  Therefore, we have experienced relatively minimal bad debts from hospital customers.  In limited circumstances, we have written off minimal bad debts as the result of the termination of foreign distributors.  The most significant write-offs over our history have come from U.S. packers who bundle our products in surgical trays.

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The allowance is based upon historical experience and a review of individual customer balances.  If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.  Our bad debt reserve was $544,285 at March 31, 2007, which is in line with historical collection experience.

Stock-Based Compensation:  We account for stock-based compensation in accordance with SFAS No. 123(R), Share-Based Payment. Under the fair value recognition provisions of this statement, we measure share-based compensation cost at the grant date based on the value of the award and is recognized as expense over the vesting period.   Judgment is required in estimating the amount of share-based awards that are expected to be forfeited.  If actual results differ significantly from these estimates, stock-based compensation expense and our results of operations could be materially impacted.

Income Taxes: We adopted the provisions of FIN 48, effective January 1, 2007. Under FIN 48, tax positions shall initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions shall initially and subsequently be measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts.  Although we believe our provisions for FIN 48 unrecognized tax positions are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our income tax provisions and accruals. The tax law is subject to varied interpretations, and we have taken positions related to certain matters where the law is subject to interpretation.  Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.

ITEM 3:   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our principal market risk relates to changes in the value of the Euro and Great Britain Pound (“GBP”) relative to the value of the U.S. Dollar.  Our consolidated financial statements are denominated in the U.S. Dollar, our principal currency.  A portion of our revenues ($5.7 million, representing approximately 11.3% of aggregate revenues), for the quarter ended March 31, 2007 was attributable to sales that were denominated in Euros and GBPs.  Certain of our expenses are also denominated in Euros and GBPs, which partially offsets risks associated with fluctuations of exchanges rates between the Euro and GBP on the one hand, and the U.S. Dollar on the other hand.  Because of our Euro and GBP-denominated revenues and expenses, in a year in which our Euro and GBP-denominated revenues exceed our Euro and GBP-based expenses, the value of such Euro and GBP-denominated net income increases if the value of the Euro and GBP increase relative to the value of the U.S. Dollar, and decreases if the value of the Euro and GBP decrease relative to the value of the U. S. Dollar.  During the quarter ended March 31, 2007, the exchange rate between the Euro and GBP against the U.S. Dollar resulted in an increase of our gross revenues of approximately $505,000 and 0.17% in gross profit.

At March 31, 2007, we had a net exposure representing the difference between Euro and GBP denominated receivables and Euro and GBP denominated payables of approximately 1,166,000 million and 382,000, respectively.  In order to partially offset such risks, at February 28, 2007, we entered into 30-day forward contract for Euro and GBP.  We generally enter into similar economic transactions at various times during the year to partially offset exchange rate risks we bear throughout the year.  We do not purchase or hold derivative financial instruments for speculative or trading purposes.  During the quarter ended March  31, 2007 we recorded a net loss of approximately $17,000 on these transactions executed during the quarter ended March 31, 2007, in an effort to limit our exposure to fluctuations in the Euro and GBP against the U.S. Dollar exchange rate.

As of March 31, 2007, we had no variable rate debt. As long as we do not have variable rate debt, our interest expense would not be affected by changes in interest rates.

15

ITEM 4:   CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures

An evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2007 was performed under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer.  Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by Merit in reports filed or submitted by Merit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported as specified in the SEC’s rules and forms.

(b) Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended March 31, 2007 that materially affected, or that we believe is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1A.   RISK FACTORS

In addition to other information set forth in this Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2006, which could materially affect our business, financial condition or future results.  The risks described in our Annual Report on Form 10-K are not the only risks facing Merit.  Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results.

ITEM 6: EXHIBITS

16

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MERIT MEDICAL SYSTEMS, INC.

REGISTRANT

17

Exhibit 10.19

STOCK PURCHASE AGREEMENT

THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into this 1st day of APRIL, 2007, by and between SHEEN MAN CO. LTD, a  Japanese corporation (“Seller”), and MERIT MEDICAL SYSTEMS, INC., a Utah corporation (“Buyer”), based on the following:

Premises

A.            Seller is the owner of  Three Hundred Forty Four Thousand and Eighty Four (344,084) shares of the common stock, no par value per share, of Merit Medical Systems, Inc. (the “Common Stock”);

B.            Seller wishes to sell, and Buyer wishes to purchase, the Shares on the terms and subject to the conditions set forth in this Agreement

Agreement

NOW, THEREFORE, based on the foregoing premises, which are incorporated herein by this reference, and for and in consideration of the mutual promises and covenants hereinafter set forth and the benefit to the parties to be derived therefrom, the receipt, adequacy and legal sufficiency of which are  hereby acknowledged, Buyer and Seller agree as follows:

1.             Purchase and Sale of Common Stock.  On the terms and subject to the conditions set forth in this Agreement, Seller agrees to sell, convey, and transfer to Buyer an aggregate of Three Hundred Forty Four Thousand and Eighty Four (344,084) shares of Common Stock held of record by Seller (the “Shares”), and Buyer agrees to purchase such Shares from Seller, at a purchase price of $11.797 per Share for a total Purchase Price of Four Million Fifty Nine Thousand One Hundred Fifty Eight Dollars and Ninety Five Cents ($4,059,158.95 US Dollars).   Payment of the aggregate purchase price for the Shares shall be made by Buyer at the Closing in US Dollars (as defined below) by wire transfer.

2.             The Closing.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place on or before April 4, 2007 (the “Closing Date”).  The Closing is subject to the satisfaction of the terms and conditions of this Agreement, and shall be held on the Closing Date at the offices of Buyer, or such other time and place as may be agreed to by the parties.

3.             Deliveries at Closing.  Contemporaneously with, and as a condition precedent to, the delivery of the purchase price to Seller, Seller shall deliver to Buyer certificates representing the Shares, duly endorsed by the record owner thereof, or accompanied by duly executed assignment documents, with all required signatures medallion guaranteed by a securities broker-dealer or bank.

4.             Representations and Warranties of Seller.  Seller makes and delivers the following representations and warranties to Buyer with the express intention that Buyer rely upon such representations and warranties and with the knowledge that Buyer will rely upon same:

(a)           Seller has all requisite power and authority to enter into this Agreement and to perform all of [his/its] obligations under this Agreement.  Seller is not a party to, subject to, or bound by any mortgage, deed of trust, loan agreement, security agreement, lien, or other agreement or instrument of any kind, or any judgment, order, writ, or injunction or decree of any

court or governmental body that conflicts with Seller’s obligations under this Agreement or that will prohibit, prevent, or affect the carrying out of the transactions contemplated by this Agreement or the performance by Seller of any obligations hereunder.

(b)           Seller is the sole legal and beneficial owner of all of the Shares, free and clear of any lien, claim, demand, encumbrance, security interest, or restriction on transfer of any nature whatsoever and Seller has full right, power, and authority to sell and transfer the Shares to Buyer pursuant to the terms of this Agreement and, upon delivery of the Shares to Buyer, Buyer will acquire good and marketable title to all of the Shares, free and clear of any liens, claims, demands, encumbrances, security interests, or restrictions on transfer, other than restrictions imposed by federal and state securities laws.

(c)           Seller has not entered into any agreement or incurred any liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to the sale of the Shares by Seller.

(d)           Seller has reviewed the public reports of Buyer, including:

·                  Buyer’s Annual Report on Form 10-K for the year ended December 31, 2006.

(e)           Seller has been given an opportunity to ask questions of and receive answers from, the directors, officers and employees of Buyer concerning the business, assets, operations, and plans of Buyer and to obtain any additional information concerning Buyer, the Common Stock and the Shares requested by Seller.  Seller has been informed that Buyer is considering a number of business alternatives that potentially could affect the value of an investment in Buyer, including the possibility of Buyer’s acquisition of other enterprises or assets, Buyer’s pursuit and/or completion of strategic transactions and other potential alternatives which could affect, and might materially affect, the value of the Common Stock in general and the Shares in particular.

(f)            Seller is entering into this Agreement based on [his/its] desire for liquidity and [his/its] own independent business purposes.  Seller is not selling the Shares based on any representation or warranty or other inducement (other than the express terms and conditions set forth in this Agreement) of Buyer or of any of Buyer’s directors, officers, or employees with respect to the assets, business, operations, or plans of Buyer or with respect to the Common Stock or the trading market for the Common Stock.  In reaching [his/its] decision to sell the Shares to Buyer, Seller has relied solely on [his/its] review of the available public information concerning Buyer and independent investigations made by Buyer and [his/its] representatives.  In determining to sell the Shares, Seller acknowledges that Buyer may well enjoy substantial business and financial success, the price which Seller is receiving for the Shares may be substantially less than the potential value of the Common Stock, and the utilization of the sales proceeds by Seller may not be as profitable as a retained ownership in Buyer.  Notwithstanding the foregoing, Seller wishes to sell the Shares to Buyer.

(g)           All representations and warranties of Seller set forth in this Agreement or in any other written statement or document delivered by Seller in connection with the transactions contemplated hereby will be true and correct in all respects on and as of the Closing Date and will survive the consummation of the transactions contemplated by this Agreement.

(h)           Seller understands the meaning and legal consequences of the representations and warranties contained in this Agreement and agrees to indemnify and hold harmless Buyer and its directors and officers from and against any and all loss, damage, or liability due to or arising out

2

of a breach of or the inaccuracy of any representation or warranty of Seller set forth in this Agreement.  Notwithstanding any of the representations, warranties, acknowledgments, or agreements made herein by Seller, Seller does not hereby or in any other manner waive any right granted to Seller under federal or state securities laws.

5.             Representation of Buyer.  Buyer has taken all corporate action necessary to duly authorize the transactions contemplated by this Agreement and has all requisite power and authority to enter into this Agreement and to perform all of its obligations under this Agreement.  Buyer is not a party to, subject to, or bound by any mortgage, deed of trust, loan agreement, security agreement, lien, or other agreement or instrument of any kind, or any judgment, order, writ, or injunction or decree of any court or governmental body that conflicts with Buyer’s obligations under this Agreement or that will prohibit, prevent, or affect the carrying out of the transactions contemplated by this Agreement or the performance by Buyer of any obligations hereunder.

6.             Conditions to Buyer’s Obligations.  The obligation of Buyer to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the following conditions:  (i) the representations and warranties of Seller herein contained shall be true and correct in all material respects on and as of the Closing Date with the same effect as though made as of such date; and (ii) all necessary filings and/or actions required by applicable securities laws or the rules of any exchange on which the Common Stock trades shall have been completed.  Prior to the delivery of the purchase price to Seller, Seller shall have delivered the certificates representing the Shares to Buyer as required by Section 3 above.

7.             Conditions to Seller’s Obligations.  The obligation of Seller to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the following conditions:  (i) the representations and warranties of Buyer herein contained shall be true and correct in all material respects on and as of the Closing Date with the same effect as though made as of such date; and (ii) Buyer shall deliver the purchase price as required by paragraph 3.

8.             Termination.  This Agreement may be terminated at the election of either Buyer or Seller, if any one or more of the conditions to its obligations herein shall not have been fulfilled by April 4, 2007.  This Agreement may also be terminated at any time prior to the Closing by mutual consent of the parties.  Any termination hereunder shall not limit or otherwise affect the rights of a party against the other arising from a breach of, or failure to perform as required by, this Agreement.

9.             Confidential Information.  Seller (i) acknowledges that the information concerning Buyer that may be provided to him in connection with his inquiries may include proprietary and non-public information (the “Confidential Information”); (ii) warrants to Buyer that he shall not use, disclose, or disseminate the Confidential Information, except for the sole and isolated purpose of making decisions related to the sale of the Shares pursuant to this Agreement (but not with respect to any transaction in the public trading market); and (iii) represents and warrants that [he/it] has not distributed or disseminated, nor will [he/it] at any time distribute or disseminate, the Confidential Information to anyone other than personal advisors of the Seller, and that the use of the Confidential Information by any personal advisor has been, and will at all times, be limited to the sole and isolated purpose of evaluating the proposed sale of the Shares pursuant to this Agreement.  Seller acknowledges that securities laws prohibit Seller from participating in the public market for the Common Stock while in the possession of material non-public information.

10.           Survival.  The representations and warranties of the respective parties set forth herein shall survive the date of closing, the consummation of the transactions contemplated in this Agreement, and the delivery of the Shares pursuant hereto.

3

11.           Governing Law.  This Agreement shall be governed by and construed under and in accordance with the laws of the State of Utah.

12.           Entire Agreement.  This Agreement represents the entire agreement between the parties relating to the subject matter hereof, and there are no other courses of dealings, understandings, agreements, representations or warranties, written or oral, except as set forth herein.  No amendment or modification hereof shall be effective until and unless the same shall have been set forth in writing and signed by the parties hereto.

13.           Severability.  If any provision of this Agreement or the application of such provisions to any person or circumstance shall be held invalid or unenforceable, the remainder of this Agreement or the application of such provisions to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be effected thereby.

14.           Attorneys’ Fees.  If any suit, action, or proceeding is brought to enforce any term or provision of this Agreement, the prevailing party shall be entitled to recover reasonable attorneys’ fees, costs, and expenses incurred, in addition to any other relief to which such party may be legally entitled.

15.           Execution in Counterparts.  This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.

16.           No Waiver.  Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, in law, or in equity, and may be enforced concurrently herewith, and no waiver by any party of the performance of any obligation of the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.

17.           Expenses.  Each of the parties shall bear its own costs and expenses, including legal fees, incurred in connection with this Agreement and the transactions contemplated hereby.

18.           No Third-Party Beneficiaries.  This Agreement is for the sole benefit of the parties hereto and nothing herein expressed or implied shall give, or be construed to give, any other person any legal or equitable rights hereunder.

[REMAINDER OF PAGE INTENTIONTALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS]

4

IN WITNESS WHEREOF, the parties to this Agreement have executed the same as of the date first above written.

5

Exhibit 31.1

CERTIFICATION

I, Fred P. Lampropoulos, certify that:

1.      I have reviewed this quarterly report on Form 10-Q of Merit Medical Systems, Inc. for the quarter ended March 31, 2007;

2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report;

4.      The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2007

Exhibit 31.2

CERTIFICATION

I, Kent W. Stanger, certify that:

1.      I have reviewed this quarterly report on Form 10-Q of Merit Medical Systems, Inc. for the quarter ended March 31, 2007;

2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report;

4.      The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2007

EXHIBIT 32.1

Certification of Chief Executive Officer
Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002

In connection with this Quarterly Report on Form 10-Q of Merit Medical Systems, Inc. for the quarter ended March 31, 2007, I, Fred P. Lampropoulos, Chief Executive Officer of Merit Medical Systems, Inc., certify, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)   The report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)   The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of Merit Medical Systems, Inc.

This certification accompanies the foregoing report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.  A signed original of this certification has been provided to the registrant and will be retained by the registrant and furnished to the Securities and Exchange Commission or its staff upon request.

EXHIBIT 32.2

Certification of Chief Financial Officer
Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002

In connection with this Quarterly Report on Form 10-Q of Merit Medical Systems, Inc. for the quarter ended March 31, 2007, I, Kent W. Stanger, Chief Financial Officer of Merit Medical Systems, Inc., certify, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)   The report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)   The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of Merit Medical Systems, Inc.

This certification accompanies the foregoing report pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.  A signed original of this certification has been provided to the registrant and will be retained by the registrant and furnished to the Securities and Exchange Commission or its staff upon request.